Off-the-shelf third-party HSC-engineered iNKT cells for ameliorating GvHD while preserving GvL effect in the treatment of blood cancers

Allo-HSCT is a curative therapy for hematologic malignancies owing to GvL effect mediated by alloreactive T cells; however, the same T cells also mediate GvHD, a severe side effect limiting the widespread application of allo-HSCT in clinics. Invariant natural killer T (iNKT) cells can ameliorate GvH...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yan-Ruide, Zeng, Samuel, Dunn, Zachary Spencer, Zhou, Yang, Li, Zhe, Yu, Jiaji, Wang, Yu-Chen, Ku, Josh, Cook, Noah, Kramer, Adam, Yang, Lili
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399487/
https://www.ncbi.nlm.nih.gov/pubmed/36034226
http://dx.doi.org/10.1016/j.isci.2022.104859

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399487/
https://www.ncbi.nlm.nih.gov/pubmed/36034226
http://dx.doi.org/10.1016/j.isci.2022.104859

Ejemplares similares